Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio

July 13, 2022

Enveric Biosciences to Participate in Upcoming Conferences in June 2022

June 8, 2022

Enveric Biosciences to Participate in the Microdose Psychedelic Capital Conference on May 26, 2022

May 24, 2022

Enveric Biosciences to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022

May 17, 2022

Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders

May 11, 2022

Enveric Biosciences to Host Fireside Chat with Dr. Bob Dagher, Chief Medical Officer, on May 17th at 10:00 a.m. ET

May 5, 2022

Enveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

May 3, 2022

Enveric Biosciences to Participate in Upcoming Investor Conferences in April 2022

April 6, 2022

Enveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update

March 31, 2022

Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

March 29, 2022

‹
1
…
12
13
14
15
16
…
18
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2026 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.